JP2021516232A5 - - Google Patents
Info
- Publication number
- JP2021516232A5 JP2021516232A5 JP2020545562A JP2020545562A JP2021516232A5 JP 2021516232 A5 JP2021516232 A5 JP 2021516232A5 JP 2020545562 A JP2020545562 A JP 2020545562A JP 2020545562 A JP2020545562 A JP 2020545562A JP 2021516232 A5 JP2021516232 A5 JP 2021516232A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- chloro
- methoxy
- inden
- dihydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862637009P | 2018-03-01 | 2018-03-01 | |
| US62/637,009 | 2018-03-01 | ||
| PCT/US2019/020032 WO2019169123A1 (en) | 2018-03-01 | 2019-02-28 | Compounds useful as immunomodulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021516232A JP2021516232A (ja) | 2021-07-01 |
| JP2021516232A5 true JP2021516232A5 (enExample) | 2023-05-29 |
| JP7326306B2 JP7326306B2 (ja) | 2023-08-15 |
Family
ID=65729475
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020545562A Active JP7326306B2 (ja) | 2018-03-01 | 2019-02-28 | 免疫調節剤として有用な化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11578054B2 (enExample) |
| EP (1) | EP3759093B1 (enExample) |
| JP (1) | JP7326306B2 (enExample) |
| KR (1) | KR102758923B1 (enExample) |
| CN (1) | CN112041312A (enExample) |
| ES (1) | ES2933601T3 (enExample) |
| WO (1) | WO2019169123A1 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10639284B2 (en) * | 2016-06-27 | 2020-05-05 | Chemocentryx, Inc. | Immunomodulator compounds |
| CN110461829B (zh) | 2017-03-27 | 2023-02-28 | 百时美施贵宝公司 | 作为免疫调节剂的取代的异喹啉衍生物 |
| WO2018200571A1 (en) | 2017-04-25 | 2018-11-01 | Arbutus Biopharma Corporation | Substituted 2,3-dihydro-1h-indene analogs and methods using same |
| US10919852B2 (en) | 2017-07-28 | 2021-02-16 | Chemocentryx, Inc. | Immunomodulator compounds |
| US10392405B2 (en) | 2017-08-08 | 2019-08-27 | Chemocentryx, Inc. | Macrocyclic immunomodulators |
| KR102738303B1 (ko) | 2018-01-23 | 2024-12-03 | 브리스톨-마이어스 스큅 컴퍼니 | 면역조정제로서 유용한 2,8-디아실-2,8-디아자스피로[5.5]운데칸 화합물 |
| US10568874B2 (en) | 2018-02-22 | 2020-02-25 | Chemocentryx, Inc. | Indane-amines as PD-L1 antagonists |
| US12083118B2 (en) | 2018-03-29 | 2024-09-10 | Arbutus Biopharma Corporation | Substituted 1,1′-biphenyl compounds, analogues thereof, and methods using same |
| US20210236476A1 (en) * | 2018-08-29 | 2021-08-05 | Chemocentryx, Inc. | Methods of treating cancer with small molecule pd-l1 inhibitors |
| WO2020198676A1 (en) | 2019-03-28 | 2020-10-01 | Bristol-Myers Squibb Company | Methods of treating tumor |
| KR20210146348A (ko) | 2019-03-28 | 2021-12-03 | 브리스톨-마이어스 스큅 컴퍼니 | 종양을 치료하는 방법 |
| WO2020232256A1 (en) | 2019-05-15 | 2020-11-19 | Chemocentryx, Inc. | Triaryl compounds for treatment of pd-l1 diseases |
| KR20220016155A (ko) | 2019-05-30 | 2022-02-08 | 브리스톨-마이어스 스큅 컴퍼니 | 면역-종양학 (i-o) 요법에 적합한 대상체를 확인하는 방법 |
| US20220363760A1 (en) | 2019-05-30 | 2022-11-17 | Bristol-Myers Squibb Company | Multi-tumor gene signature for suitability to immuno-oncology therapy |
| WO2020243570A1 (en) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Cell localization signature and combination therapy |
| WO2020257549A2 (en) | 2019-06-20 | 2020-12-24 | Chemocentryx, Inc. | Compounds for treatment of pd-l1 diseases |
| BR112021025888A2 (pt) | 2019-07-10 | 2022-04-26 | Chemocentryx Inc | Indanos como inibidores de pd-l1 |
| CN112457305B (zh) * | 2019-09-09 | 2025-01-10 | 上海长森药业有限公司 | 含三环结构的芳香杂环化合物，及其制备方法和应用 |
| WO2021055994A1 (en) | 2019-09-22 | 2021-03-25 | Bristol-Myers Squibb Company | Quantitative spatial profiling for lag-3 antagonist therapy |
| JP7736678B2 (ja) | 2019-10-16 | 2025-09-09 | ケモセントリックス，インコーポレイティド | Ｐｄ－ｌ１疾患の処置のためのヘテロアリール－ビフェニルアミド |
| ES3064674T3 (en) | 2019-10-16 | 2026-04-28 | Chemocentryx Inc | Heteroaryl-biphenyl amines for the treatment of pd-l1 diseases |
| US20220411499A1 (en) | 2019-11-08 | 2022-12-29 | Bristol-Myers Squibb Company | LAG-3 Antagonist Therapy for Melanoma |
| IL300813A (en) | 2020-08-28 | 2023-04-01 | Bristol Myers Squibb Co | LAG-3 antagonist therapy for hepatocellular carcinoma |
| AU2021334361A1 (en) | 2020-08-31 | 2023-05-11 | Bristol-Myers Squibb Company | Cell localization signature and immunotherapy |
| KR20230093282A (ko) | 2020-10-23 | 2023-06-27 | 브리스톨-마이어스 스큅 컴퍼니 | 폐암에 대한 lag-3 길항제 요법 |
| WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
| CN117858719A (zh) | 2021-03-29 | 2024-04-09 | 朱诺治疗学股份有限公司 | 使用检查点抑制剂疗法和car t细胞疗法的组合进行给药和治疗的方法 |
| KR20240004801A (ko) * | 2021-05-05 | 2024-01-11 | 브리스톨-마이어스 스큅 컴퍼니 | 면역조절제로서 유용한 락톤 및 락탐 함유 화합물 |
| CA3224890A1 (en) | 2021-10-29 | 2023-05-04 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for hematological cancer |
| KR20240135661A (ko) | 2022-01-26 | 2024-09-11 | 브리스톨-마이어스 스큅 컴퍼니 | 간세포성 암종에 대한 조합 요법 |
| JP7851417B2 (ja) | 2022-04-08 | 2026-04-24 | ブリストル－マイヤーズ スクイブ カンパニー | 三次リンパ組織様構造の機械学習識別、分類、及び定量化 |
| EP4638503A1 (en) | 2022-12-21 | 2025-10-29 | Bristol-Myers Squibb Company | Combination therapy for lung cancer |
| WO2024196952A1 (en) | 2023-03-20 | 2024-09-26 | Bristol-Myers Squibb Company | Tumor subtype assessment for cancer therapy |
| WO2025245489A1 (en) | 2024-05-24 | 2025-11-27 | Bristol-Myers Squibb Company | Treatment of tumors in subjects having fgl-1 positive samples |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6410690B1 (en) | 1995-06-07 | 2002-06-25 | Medarex, Inc. | Therapeutic compounds comprised of anti-Fc receptor antibodies |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5922845A (en) | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
| TW200815377A (en) | 2006-04-24 | 2008-04-01 | Astellas Pharma Inc | Oxadiazolidinedione compound |
| CN105705489B (zh) | 2013-09-04 | 2019-04-26 | 百时美施贵宝公司 | 用作免疫调节剂的化合物 |
| US9850225B2 (en) | 2014-04-14 | 2017-12-26 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| US10745382B2 (en) | 2015-10-15 | 2020-08-18 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| US10639284B2 (en) * | 2016-06-27 | 2020-05-05 | Chemocentryx, Inc. | Immunomodulator compounds |
| EA201990221A1 (ru) | 2016-07-08 | 2019-06-28 | Бристол-Маерс Сквибб Компани | 1,3-дигидроксифенильные производные, применимые в качестве иммуномодуляторов |
| US10144706B2 (en) | 2016-09-01 | 2018-12-04 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| EP3558970B1 (en) | 2016-12-20 | 2021-09-01 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| CN110461829B (zh) | 2017-03-27 | 2023-02-28 | 百时美施贵宝公司 | 作为免疫调节剂的取代的异喹啉衍生物 |
| US10919852B2 (en) * | 2017-07-28 | 2021-02-16 | Chemocentryx, Inc. | Immunomodulator compounds |
| KR102738303B1 (ko) | 2018-01-23 | 2024-12-03 | 브리스톨-마이어스 스큅 컴퍼니 | 면역조정제로서 유용한 2,8-디아실-2,8-디아자스피로[5.5]운데칸 화합물 |
-
2019
- 2019-02-28 CN CN201980028083.6A patent/CN112041312A/zh active Pending
- 2019-02-28 KR KR1020207027712A patent/KR102758923B1/ko active Active
- 2019-02-28 EP EP19710566.1A patent/EP3759093B1/en active Active
- 2019-02-28 JP JP2020545562A patent/JP7326306B2/ja active Active
- 2019-02-28 WO PCT/US2019/020032 patent/WO2019169123A1/en not_active Ceased
- 2019-02-28 US US16/977,374 patent/US11578054B2/en active Active
- 2019-02-28 ES ES19710566T patent/ES2933601T3/es active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021516232A5 (enExample) | ||
| RU2413727C2 (ru) | Производные пиразола и их применение в качестве ингибиторов рецепторных тирозинкиназ | |
| RU2469036C2 (ru) | Имидазопиридиновые ингибиторы киназ | |
| RU2373209C2 (ru) | Пирролотриазиновые соединения как ингибиторы киназ | |
| RU2365588C2 (ru) | Хиназолиновые соединения | |
| RU2497822C2 (ru) | Селективные к bcl-2 агенты, вызывающие апоптоз, для лечения рака и иммунных заболеваний | |
| RU2388750C2 (ru) | Ингибиторы фосфодиэстеразы 4, включая аналоги n-замещенного диариламина | |
| JP2023123854A5 (enExample) | ||
| RU2006126974A (ru) | Амидное производное и лекарственное средство | |
| JP2023501253A5 (enExample) | ||
| RU2437882C2 (ru) | Производные имидазолидинона | |
| JP2022551422A5 (enExample) | ||
| JP2016538313A5 (enExample) | ||
| IL291590B2 (en) | Novel substituted quinoline-8-carbonitrile derivatives having androgen receptor degradation activity and uses thereof | |
| RU2013151174A (ru) | Замещенные пиримидинилпирролы, активные в качестве ингибиторов киназы | |
| RU2009117705A (ru) | Производные 2-аминокарбонилпиридина | |
| JP2012528178A5 (enExample) | ||
| RU2010110640A (ru) | Соединения и композиции 5-(4-(галогеналкокси)фенил)пиримидин-2-амина в качестве ингибиторов киназ | |
| RU2012127760A (ru) | Bcl-2-селективные апоптоз-индуцирующие средства для лечения рака и иммунных заболеваний | |
| RU2012104493A (ru) | Замещенные соединения пиразоло [1,5-a] пиримидина как ингибиторы киназы trk | |
| JP2005511543A5 (enExample) | ||
| RU2011141121A (ru) | Пролекарственные формы ингибиторов киназ и их применение в терапии | |
| JP2015533177A5 (enExample) | ||
| RU2008112221A (ru) | Соединения ряда изоиндолимидов, их композиции и способы применения | |
| RU2018104868A (ru) | 2-амино-3-фтор-3-(фторметил)-6-метил-6-фенил-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1 |